DK2758076T3 - COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR - Google Patents
COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR Download PDFInfo
- Publication number
- DK2758076T3 DK2758076T3 DK12761739.7T DK12761739T DK2758076T3 DK 2758076 T3 DK2758076 T3 DK 2758076T3 DK 12761739 T DK12761739 T DK 12761739T DK 2758076 T3 DK2758076 T3 DK 2758076T3
- Authority
- DK
- Denmark
- Prior art keywords
- inh
- ivig
- administered
- immunoglobulin
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161538832P | 2011-09-24 | 2011-09-24 | |
| PCT/EP2012/068643 WO2013041677A1 (en) | 2011-09-24 | 2012-09-21 | Combination therapy using immunoglobulin and c1-inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2758076T3 true DK2758076T3 (en) | 2019-04-01 |
Family
ID=46881067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12761739.7T DK2758076T3 (en) | 2011-09-24 | 2012-09-21 | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10471142B2 (https=) |
| EP (1) | EP2758076B1 (https=) |
| JP (1) | JP6190368B2 (https=) |
| KR (1) | KR101956585B1 (https=) |
| CN (1) | CN104010656B (https=) |
| AU (1) | AU2012311483B2 (https=) |
| DK (1) | DK2758076T3 (https=) |
| ES (1) | ES2714999T3 (https=) |
| WO (1) | WO2013041677A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9352016B2 (en) | 2011-03-09 | 2016-05-31 | Csl Behring Gmbh | Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| ES2609070T3 (es) * | 2013-02-28 | 2017-04-18 | Csl Behring Gmbh | Agente terapéutico para el embolismo de líquido amniótico |
| CN105188750A (zh) | 2013-03-08 | 2015-12-23 | 德国杰特贝林生物制品有限公司 | 治疗和预防远端缺血-再灌注损伤 |
| RS58351B1 (sr) | 2013-03-15 | 2019-03-29 | Shire Viropharma Inc | C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze |
| HUE044737T2 (hu) * | 2013-05-06 | 2019-11-28 | Baxalta Inc | Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel |
| EP4162947A1 (en) * | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| JP7109160B2 (ja) | 2014-06-18 | 2022-07-29 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法 |
| US20180036394A1 (en) * | 2015-02-20 | 2018-02-08 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| CA2986957A1 (en) | 2015-06-03 | 2016-12-08 | Children's Hospital Medical Center | Compositions and methods for treating neonatal biliary atresia |
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| WO2022251654A1 (en) * | 2021-05-28 | 2022-12-01 | West Virginia University Board of Governors on behalf of West Virginia University | Mitoneet ligands for use in protection from tissue ischemic reperfusion injury |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2009158A (en) * | 1934-08-01 | 1935-07-23 | Ophthalmological Foundation In | Ophthalmic ergograph |
| DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| DE4244735A1 (de) | 1992-08-24 | 1994-03-31 | Behringwerke Ag | Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen |
| US5827832A (en) | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
| US7053176B1 (en) | 1999-09-16 | 2006-05-30 | Altana Pharma Ag | Combination of C1-INH and lung surfactant for the treatment of respiratory disorders |
| US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| US8053569B2 (en) * | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| PL2380587T3 (pl) | 2005-12-21 | 2018-03-30 | Pharming Intellectual Property B.V. | Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu |
| US20100143325A1 (en) * | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| EP2233499A1 (en) * | 2009-03-26 | 2010-09-29 | CSL Behring AG | Antibody composition with altered Fab sialylation |
| TWI445714B (zh) | 2009-05-27 | 2014-07-21 | Baxter Int | 產製用於皮下使用之高濃度免疫球蛋白製備物之方法 |
-
2012
- 2012-09-21 KR KR1020147010605A patent/KR101956585B1/ko active Active
- 2012-09-21 WO PCT/EP2012/068643 patent/WO2013041677A1/en not_active Ceased
- 2012-09-21 CN CN201280046349.8A patent/CN104010656B/zh active Active
- 2012-09-21 AU AU2012311483A patent/AU2012311483B2/en active Active
- 2012-09-21 US US14/346,478 patent/US10471142B2/en active Active
- 2012-09-21 ES ES12761739T patent/ES2714999T3/es active Active
- 2012-09-21 JP JP2014531244A patent/JP6190368B2/ja active Active
- 2012-09-21 DK DK12761739.7T patent/DK2758076T3/en active
- 2012-09-21 EP EP12761739.7A patent/EP2758076B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140075753A (ko) | 2014-06-19 |
| CN104010656B (zh) | 2016-02-24 |
| HK1200334A1 (en) | 2015-08-07 |
| CA2848510A1 (en) | 2013-03-28 |
| US20140234293A1 (en) | 2014-08-21 |
| EP2758076B1 (en) | 2018-12-12 |
| AU2012311483B2 (en) | 2016-03-10 |
| KR101956585B1 (ko) | 2019-03-11 |
| JP2014526541A (ja) | 2014-10-06 |
| US10471142B2 (en) | 2019-11-12 |
| WO2013041677A1 (en) | 2013-03-28 |
| ES2714999T3 (es) | 2019-05-31 |
| EP2758076A1 (en) | 2014-07-30 |
| JP6190368B2 (ja) | 2017-08-30 |
| CN104010656A (zh) | 2014-08-27 |
| AU2012311483A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2758076T3 (en) | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR | |
| TWI831106B (zh) | 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物 | |
| US9561263B2 (en) | Treatment of inflammatory illnesses with ACE2 | |
| Leong et al. | Immunological cross-reactivity and neutralization of the principal toxins of Naja sumatrana and related cobra venoms by a Thai polyvalent antivenom (Neuro Polyvalent Snake Antivenom) | |
| WO2015054569A1 (en) | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein | |
| NZ719724A (en) | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor | |
| US20140249087A1 (en) | Use of hemopexin to sequester hemoglobin | |
| US20220339233A1 (en) | Compositions and methods for preventing recurrence of cancer | |
| CN111447950B (zh) | 活性调节剂 | |
| US20180117126A1 (en) | Treatment of inflammatory illnesses with ace2 | |
| CA2848510C (en) | Combination therapy using immunoglobulin and c1-inhibitor | |
| Bessette et al. | Oral administration of a casein matrix containing β-casofensin protects the intestinal barrier in two preclinical models of gut diseases | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| HK1200334B (en) | Combination therapy using immunoglobulin and c1-inhibitor | |
| JP2010535199A (ja) | コハク酸を含む鼻腔内医薬品組成物 | |
| JP2009190994A (ja) | 抗インフルエンザウイルス剤、及びその有効成分の製造方法 | |
| US20240150441A1 (en) | Monoclonal antibodies against sars-cov-2 and variants | |
| RU2473364C2 (ru) | Способ лечения клещевого энцефалита | |
| JP2026507289A (ja) | デノスマブ製剤 | |
| Imhof et al. | Miscellaneous antibacterial | |
| HK1230094A1 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JPH08169845A (ja) | ヒト由来アンチトロンビン−ｉｉｉの新規用途 | |
| FR2967071A1 (fr) | Facteur h pour le traitement de maladies auto-immunes du systeme nerveux |